From 29/08 to 1/09, Roger Prades, Iproteos CSO, participated at the 28th ECNP Congress of Applied and Translational Neuroscience. His abstract was selected for poster oral presentation, which was given on 30th of August. “It has been a very positive experience. Lots of scientists and physicians came around the poster to know a little bit more about IPR19, the cognitive enhancer we are developing at Iproteos”, has declared Roger after the ECNP Congress. Apart of his talk, attendees approached him during the poster sessions to ask details of the project: “I was amazed at the high scientific quality of the attendees and at their interesting questions”. Dr. Prades poster contained a summary of the most relevant experiments performed with the cognitive enhancer IPR19 in animal models. “Non-regulatory preclinical studies of IPR19 have finished with positive results. We have been able to observe improvement in the working memory of schizophrenia mice treated with our drug. Based on that, we are optimistic for the regulatory preclinical phase, which is about to start”, says Roger.
Roger Prades during the oral presentation